Back to Agenda
Update on FDA's Real-World Evidence Program: Current FDA Demonstration Projects
Session Chair(s)
John Concato, MD, MPH, MS
Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA, United States
This session will combine an update on FDA’s Real-World Evidence (RWE) Program for drugs and biologic products with a discussion of interim results from ongoing trial replication analyses that advance our understanding of whether and how observational studies can contribute to evidence of the effectiveness of drug products.
Learning Objective : Describe the current status of FDA’s RWE Program; report on results from the RCT-DUPLICATE project emulating randomized trials with analyses of real-world data (RWD); Identify emerging insights from trial replication efforts.
Speaker(s)
FDA Update
John Concato, MD, MPH, MS
FDA, United States
Associate Director for Real-World Evidence Analytics, OMP, CDER
FDA Update
Michael Blum, MD, MPH
FDA, United States
Deputy Director, Office of Pharmacovigilance and Epidemiology, CDER
Calibrating RWE Against RCT Evidence: Key Findings From the RCT-Duplicate Project
Sebastian Schneeweiss, DrSc, MD
Harvard Medical School and Brigham and Women's Hospital, United States
Professor, Medicine and Epidemiology; Chief of the Div of Pharmacoepidemiology
Industry Update
Robert Reynolds, DrSc, MSc, FISPE
GSK, United States
Vice President, Epidemiology & Patient-Centered Outcomes, VEO
Replication of RCTs with RWD: Potential Concerns
David Thompson, PhD
Rubidoux Research LLC, United States
Founder and Principal Consultant
Have an account?